Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products, has been rejected by the US Food and Drug Administration for the expanded use of its lead product Exparel - a post-surgery pain drug.
FDA Rejects Expanded Use Of Paciras Exparel; Stock Plunges 14% Pre-Market
Bidness etc. - 2 Mar 2015 22:24
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products, has been rejected by the US Food and Drug Administration for the expanded use of its lead product Exparel - a post-surgery pain drug.
Share this Article
Recommended